Literature DB >> 33895189

Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder.

Erica Zamberletti1, Tiziana Rubino2, Daniela Parolaro3.   

Abstract

Recent years have seen a renewed interest on the possible therapeutic exploitations of specific cannabinoids derived from the Cannabis sativa plant. Thus far, the most studied non-psychotomimetic cannabinoid is cannabidiol (CBD), which has shown promising therapeutic potential for relieving a variety of neurological diseases. However, also its propyl analogue, cannabidivarin (CBDV), has recently gained much attention as a potential therapeutic agent for the management of disabling neurological conditions. This review aims at providing a comprehensive and updated overview of the available animal and human data, which have investigated the possible therapeutic potential of CBDV for the management of epilepsy and autism spectrum disorder.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Animal models; Autism spectrum disorder; Cannabidivarin; Epilepsy; Human data

Mesh：

Substances：

Year:  2021        PMID： 33895189     DOI： 10.1016/j.pharmthera.2021.107878

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN： 0163-7258            Impact factor:   12.310


  8 in total

1.  Anandamide and 2-arachidonoylglycerol differentially modulate autistic-like traits in a genetic model of autism based on FMR1 deletion in rats.

Authors:  Sara Schiavi; Antonia Manduca; Emilia Carbone; Valeria Buzzelli; Alessandro Rava; Alessandro Feo; Fabrizio Ascone; Maria Morena; Patrizia Campolongo; Matthew N Hill; Viviana Trezza
Journal:  Neuropsychopharmacology       Date:  2022-09-16       Impact factor: 8.294

Review 2.  Role of Brain Modulators in Neurodevelopment: Focus on Autism Spectrum Disorder and Associated Comorbidities.

Authors:  Ali K Saad; Amal Akour; Abdulla Mahboob; Salahdein AbuRuz; Bassem Sadek
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-16

3.  Characterization and Biological Activity of Fiber-Type Cannabis sativa L. Aerial Parts at Different Growth Stages.

Authors:  Giulia Mastellone; Arianna Marengo; Barbara Sgorbini; Federica Scaglia; Francesca Capetti; Francesco Gai; Pier Giorgio Peiretti; Patrizia Rubiolo; Cecilia Cagliero
Journal:  Plants (Basel)       Date:  2022-02-03

4.  Cannabidivarin alleviates neuroinflammation by targeting TLR4 co-receptor MD2 and improves morphine-mediated analgesia.

Authors:  Xue Wang; Cong Lin; Siru Wu; Tianshu Zhang; Yibo Wang; Yanfang Jiang; Xiaohui Wang
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

5.  Cannabidiol Reduces Short- and Long-Term High Glutamate Release after Severe Traumatic Brain Injury and Improves Functional Recovery.

Authors:  Cindy Santiago-Castañeda; Saúl Huerta de la Cruz; Christopher Martínez-Aguirre; Sandra Adela Orozco-Suárez; Luisa Rocha
Journal:  Pharmaceutics       Date:  2022-08-02       Impact factor: 6.525

Review 6.  Minor Phytocannabinoids: A Misleading Name but a Promising Opportunity for Biomedical Research.

Authors:  Diego Caprioglio; Hawraz Ibrahim M Amin; Orazio Taglialatela-Scafati; Eduardo Muñoz; Giovanni Appendino
Journal:  Biomolecules       Date:  2022-08-06

Review 7.  Review: Cannabinoids as Medicinals.

Authors:  Jag H Khalsa; Gregory Bunt; Kenneth Blum; Sanjay B Maggirwar; Marc Galanter; Marc N Potenza
Journal:  Curr Addict Rep       Date:  2022-09-07

Review 8.  Cannabinoids: Therapeutic Use in Clinical Practice.

Authors:  Cristina Pagano; Giovanna Navarra; Laura Coppola; Giorgio Avilia; Maurizio Bifulco; Chiara Laezza
Journal:  Int J Mol Sci       Date:  2022-03-19       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.